期刊
SCIENCE
卷 369, 期 6505, 页码 793-+出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abb8008
关键词
-
资金
- ERC [309657]
- Institut Pasteur funds
- CNRS funds
- G5 Institut Pasteur Program [ANR-10-LABX-69-01]
- Milieu Interieur Program [ANR-10-LABX-69-01]
- INSERM funds
- Pasteur-Paris University (PPU) international PhD program
- Fondation-ARC
- CACSICE grant [ANR-11-EQPX-008]
- European Research Council (ERC) [309657] Funding Source: European Research Council (ERC)
Monoclonal antibodies (mAbs) targeting human antigen CD20 (cluster of differentiation 20) constitute important immunotherapies for the treatment of B cell malignancies and autoimmune diseases. Type I and II therapeutic mAbs differ in B cell binding properties and cytotoxic effects, reflecting differential interaction mechanisms with CD20. Here we present 3.7- to 4.7-angstrom cryo-electron microscopy structures of full-length CD20 in complexes with prototypical type I rituximab and ofatumumab and type II obinutuzumab. The structures and binding thermodynamics demonstrate that upon binding to CD20, type II mAbs form terminal complexes that preclude recruitment of additional mAbs and complement components, whereas type I complexes act as molecular seeds to increase mAb local concentration for efficient complement activation. Among type I mAbs, ofatumumab complexes display optimal geometry for complement recruitment. The uncovered mechanisms should aid rational design of next-generation immunotherapies targeting CD20.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据